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A b s T r A C T
haemochromatosis is a hereditary iron-overload syndrome 
caused by increased intestinal iron absorption and 
characterised by accumulation of potentially toxic iron in 
the tissues. sometimes this disease presents as a cutanea 
porphyria. we describe a patient with joint complaints 
and blistering skin lesions on sun-exposed skin. After 
identifying the porphyria cutanea tarda by urine analysis 
we found that the serum activity of uroporphyrinogen 
decarboxylase (urod) was normal, meaning a partial 
inactivation of urod in liver tissue due to external factors. 
further investigation showed the homozygous Cys282Tyr 
missense mutation and high levels of serum ferritin. it is 
important to recognise the symptoms of iron overloading at 
an early stage because hereditary haemochromatosis needs 
to be treated immediately. we therefore advocate routine 
sampling of ferritin levels in patients with unexplained 
joint complaints.
K E y w o r d s
Arthralgias, blistering skin lesions, ferritin, 
haemochromatosis, porphyria cutanea tarda
i N T r o d u C T i o N
Haemochromatosis is an iron-overload syndrome caused 
by increased intestinal absorption and characterised 
by accumulation of potentially toxic iron in the tissues. 
There are primary genetic forms expressed in adults (the 
Cys282Tyr and H63D mutations) and hereditary juvenile 
and neonatal forms. Secondary haemochromatosis can be 
a result of excessive intake of iron, augmented by the use of 
alcohol and vitamin C, and of multiple blood transfusions, 
usually seen in patients with persistent anaemias. In its 
early stages systemic iron deposition leads to mild symptoms 
such as fatigue, arthralgias and arthrosis. Untreated though, 
it can result in major organ damage such as congestive 
heart failure, cardiac arrhythmias, bronze diabetes, hepatic 
cirrhosis, impotence and infertility.1 Early recognition of 
the symptoms is of crucial importance to prevent further 
tissue destruction of the various organ systems. The direct 
or indirect effect of prolonged iron overloading on the skin 
is the first sign of haemochromatosis. We present a patient 
referred because of untreatable arthralgias of the hands and 
blistering lesions on sun-exposed skin.
C A s E  r E p o r T
A 56-year-old male presented with arthralgias, blistering 
skin lesions on sun-exposed skin and slightly raised 
liver enzymes: bilirubin 18 mmol/l (0-17), aspartate 
aminotransferase 75 U/l (<31), alanine aminotransferase 
122 U/l (<31), and g-glutamyltransferase 75 U/l (<35). He 
consumed two glasses of wine a day. The patient did 
not have any close relatives such as children, brothers 
or sisters. Physical examination did not reveal any signs 
of arthritis or an enlarged liver. However, remarkable 
blistering skin lesions on his hands and lower legs were 
seen. Ultrasound of the liver suggested steatosis hepatis 
without focal lesions. Hepatitis B/C virus, Epstein-Barr 
virus and cytomegalovirus serology were normal, as were 
serum levels of the rheumatoid factors. The differential 
diagnosis consisted of porphyria cutanea tarda (PCT) or 
parapemphigus. Subsequent 24-urine analysis revealed 
elevated levels of uroporphyrinogen III at 116 nmol/mmol 
creatinine (<2.0), hepta-carboxyl porphyrin 72 nmol/mmol 
creatinine (<1.6), hexa-carboxyl porphyrin 8.0 nmol/mmol 
creatinine (<2.4) and penta-carboxyl porphyrin 20 nmol/
mmol creatinine (<0.5), indicating partial blockage of the 
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decarboxylation of uroporphyrinogen III. The activity of 
uroporphyrinogen decarboxylase (UROD) in erythrocytes, 
which was normal, differentiated between an acquired 
and inherited subtype of PCT. To confirm the diagnosis 
of sporadic type I PCT due to iron overload in case of 
haemochromatosis, we tested ferritin levels in plasma 
(>1450 mg/l), iron saturation (105.5%) and HFE gene analysis. 
This gene turned out to be homozygously changed with 
the Cys282Tyr missense mutation. A liver biopsy was not 
performed, considering the highly invasive nature of this 
test without any clinical consequences, because there were 
no radiological and biochemical signs of fibrosis. 
Our patient was strongly advised to stop the use of 
alcohol-containing products and repeatedly underwent 
phlebotomy, resulting in a decrease in the ferritin levels of 
up to 150 mg/l with acceptable haemoglobin levels. The skin 
abnormalities disappeared rapidly and his joint complaints 
were controllable with non-steroidal anti-inflammatory 
drugs. Outpatient visits were continued to control the 
ferritin levels and six-monthly serum tests of a-fetoprotein 
levels (AFP) will be performed because of the increased 
risk of hepatocellular carcinoma in this patient.
d i s C u s s i o N
In the patient described above, hereditary haemochromatosis 
was found with a mutation in the HFE gene. Why were 
iron overload and skin blistering related here? The key 
to this question is incomplete haemsynthesis, producing 
toxic precursors. In our patient, the blockage in the 
haem pathway was found at the level of UROD which 
decarboxylates uroporphyrinogen III to coproporphyrinogen 
III in four steps producing hepta-, hexa- and penta-carboxyl 
porphyrin as by-products (figure 1; decarboxylation by-
products are not shown). The effects of iron on the 
formation of haem precursors are thought to consist of 
three cornerstones. First, iron catalyses the formation 
of reactive oxygen molecules enhancing uroporphyrin 
formation, secondly iron enhances the production of 
nonporphyrin products directly inhibiting UROD and 
thirdly iron induces d-aminolaevulinic acid synthetase 
and thus the production of d-aminolaevulinic acid, the 
precursor of uroporphyrinogen.2
Deficiency or inactivation of UROD causes 
accumulation and skin deposition of the haem precursor 
uroporphyrinogen. This molecule is potentially toxic to 
our skin because of its photosensibility for ultraviolet light 
(400 nm). The excited energy state leads to complement 
activation and release of histamine resulting in blistering 
skin lesions. Expression of this sporadic subtype of PCT 
(s-PCT) is usually observed in the third or fourth decade, 
since substantial accumulation of iron is required to 
successfully block the pathway. Hepatitis C infection, 
alcohol use and usage of oestrogens contribute to the 
expression of s-PCT.3,4 Combining these risk factors 
with hereditary or secondary derived haemochromatosis 
predisposes even more to the expression of s-PCT.5,6
Buljai et al. performed a study to investigate the correlation 
of hereditary haemochromatosis (HH) and sporadic 
porphyria cutanea tarda in an American patient population; 
they found a significantly higher incidence of s-PCT in 
homozygous HH patients compared with heterozygous 
patients and nonaffected controls.7 
The performance of liver biopsies used to be considered 
the gold standard in diagnosing haemochromatosis. With 
modern gene analysis, diagnosing HH is much easier 
and liver biopsies are only performed for prognostic 
reasons because of potential cirrhosis and hepatocellular 
carcinoma (HCC). Furthermore, several authors have 
shown that with simple clinical and biochemical variables 
(ferritin, platelet counts and aspartate aminotransferase 
values, absence of hepatomegaly) an accuracy of 77 to 
90% can be reached for correctly diagnosing the absence 
of fibrosis, thus reducing the need for liver biopsy.8,9 
Organ-specific imaging techniques such as magnetic 
resonance imaging (MRI) will be used in the evaluation 
of the HH patient in near future. Monitoring is of growing 
importance, since there is a 20-fold increased risk of 
developing HCC, especially in men. The highest risk of 
developing HCC is found in patients with established 
cirrhosis, thus screening should be focused in that 
direction. 
figure 1. The biosynthetic pathway of haem
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Eight different enzymes catalyse the formation of haem: 
1) aminolaevulinic acid synthetase,  2) aminolaevulinic acid 
dehydratase, 3) porphobilinogen deaminase, 4) uroporphyrinogen 
iii cosynthase, 5) uroporphyrinogen decarboxylase (urod), 
6) coproporphyrinogen oxidase, 7) protoporphyrinogen oxidase, 
8) ferrochelatase.
309
s e p t e m b e r  2 0 0 6 ,  V o l .  6 4 ,  N o .  8
De Geus, et al. Sporadic porphyria cutanea tarda due to haemochromatosis.
As in our patient, the recognition of the skin lesions led 
to the final diagnosis of hereditary haemochromatosis. 
In retrospection, he had a history of nonspecific joint 
complaints for two years without any significant skin 
lesions. Rheumatologists in our country usually perform 
routine blood tests containing ferritin sampling on patients 
with arthralgias. Whether or not this is cost-effective in 
screening for HH in patients with joint complaints is 
unknown, especially because of the low sensitivity and 
specificity of the test. The issue remains that we probably 
would have diagnosed our patient with HH in an earlier 
stage if we had performed a ferritin sample because of his 
joint complaints on his first visit to the outpatient clinic. 
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